Table I.
Studies on CYP17 rs743572 and Prostate Cancer
| Cases | Controls | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Author, year (Country) | ref | control source | cases/control | T/T | T/C | C/C | T/T | T/C | C/C | ethnicity |
| Sarma, 2008 (USA) | (25) | Healthy; PSA ≤4 ng/ml, normal DRE | 131/342 | 52 | 51 | 23 | 106 | 183 | 33 | African American |
| Stanford, 2002; Kwon 2012 (USA)# | (21,26) | Healthy | 30/15 | 10 | 18 | 2 | 6 | 7 | 2 | African American |
| Beuten, 2009 (USA) | 16 | Volunteers; PSA <2.5 ng/ml, normal DRE | 82/209 | 26 | 40 | 16 | 79 | 105 | 25 | African American |
| Kittles, 2001 (USA) | 19 | Healthy, screening; PSA ≤4 ng/ml, normal DRE | 71/111 | 22 | 38 | 11 | 55 | 46 | 10 | African American |
| Lunn, 1999 (USA)# | 22 | Hospital | 12/8 | 4 | 6 | 2 | 4 | 3 | 1 | African American |
| Nam, 2003 (Canada) | 23 | Hospital; normal PSA and DRE | 45/45 | African descent | ||||||
| dos Santos, 2001 (Brazil) | 17 | Blood donors; negative DRE and PSA < 2 ng/ml | 8/72 | 4 | 3 | 1 | 33 | 29 | 10 | African descent |
| Ukoli, 2011 (Nigeria)# | unp | Healthy; normal PSA and DRE | 66/93 | 32 | 26 | 8 | 44 | 37 | 12 | African |
| Jackson, 2011 (Jamaica)# | unp | Hospital; normal DRE, PSA <4 ng/ml | 114/126 | 49 | 58 | 11 | 56 | 59 | 13 | Caribbean |
|
| ||||||||||
| Total | 559/1021 | |||||||||
| META ANALYSIS | TT | T/C | C/C | T/C+C/C | |
|---|---|---|---|---|---|
| All studies | Meta OR | 1.0 (ref) | 1.26(0.95–1.67) | 1.43 (0.94–2.20) | 1.29(0.98–1.68) |
| Q-test p-value | 0.73 | 0.58 | 0.60 | ||
| I2 p-value | 0% (0–71) | 0% (0–71) | 0% (0–71) | ||
| Eggers test P-value | 0.77 | 0.55 | 0.93 | ||
|
| |||||
| African-American | Meta OR | 1.0 (ref) | 1.51 (1.01–2.26) | 2.02(1.14–3.58) | 1.62(1.10–2.37) |
| Q-test p-value | 0.62 | 0.67 | 0.65 | ||
| I2 p-value | 0% (0–85) | 0% (0–85) | 0% (0–85) | ||
| Eggers test P-value | 0.71 | 0.46 | 0.89 | ||
DRE: digital rectal examination PSA: prostate serum antigen;
#
studies included in the pooled analysis